Free Trial

Xylem Inc. (NYSE:XYL) Shares Purchased by Sumitomo Mitsui Trust Group Inc.

Xylem logo with Business Services background

Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Xylem Inc. (NYSE:XYL - Free Report) by 0.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 563,633 shares of the industrial products company's stock after buying an additional 4,116 shares during the period. Sumitomo Mitsui Trust Group Inc. owned 0.23% of Xylem worth $67,332,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Dynamic Advisor Solutions LLC acquired a new position in shares of Xylem in the 1st quarter worth approximately $694,000. Smartleaf Asset Management LLC boosted its position in Xylem by 31.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 575 shares of the industrial products company's stock valued at $67,000 after buying an additional 139 shares during the period. Triodos Investment Management BV increased its position in shares of Xylem by 12.7% during the fourth quarter. Triodos Investment Management BV now owns 234,000 shares of the industrial products company's stock worth $27,149,000 after acquiring an additional 26,300 shares during the period. Farther Finance Advisors LLC raised its position in Xylem by 30.4% in the 1st quarter. Farther Finance Advisors LLC now owns 1,797 shares of the industrial products company's stock valued at $215,000 after purchasing an additional 419 shares in the last quarter. Finally, Allianz SE purchased a new stake in shares of Xylem during the fourth quarter worth approximately $1,910,000. Hedge funds and other institutional investors own 87.96% of the company's stock.

Xylem Trading Up 0.4%

NYSE:XYL traded up $0.57 during trading hours on Friday, reaching $132.28. 713,729 shares of the company were exchanged, compared to its average volume of 1,414,526. The firm has a market cap of $32.19 billion, a price-to-earnings ratio of 35.56, a PEG ratio of 2.41 and a beta of 1.12. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.89 and a quick ratio of 1.41. The stock has a 50 day simple moving average of $125.86 and a 200 day simple moving average of $122.07. Xylem Inc. has a 52-week low of $100.47 and a 52-week high of $143.50.

Xylem (NYSE:XYL - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The industrial products company reported $1.03 EPS for the quarter, topping the consensus estimate of $0.95 by $0.08. The company had revenue of $2.07 billion during the quarter, compared to analyst estimates of $2.04 billion. Xylem had a return on equity of 10.12% and a net margin of 10.54%. During the same period in the prior year, the firm posted $0.90 earnings per share. The firm's revenue was up 1.8% on a year-over-year basis. As a group, analysts predict that Xylem Inc. will post 4.65 EPS for the current year.

Xylem Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 26th. Shareholders of record on Thursday, May 29th were paid a dividend of $0.40 per share. The ex-dividend date was Thursday, May 29th. This represents a $1.60 annualized dividend and a yield of 1.21%. Xylem's dividend payout ratio is currently 43.01%.

Wall Street Analyst Weigh In

A number of brokerages recently commented on XYL. Stifel Nicolaus boosted their target price on shares of Xylem from $140.00 to $141.00 and gave the stock a "buy" rating in a research note on Wednesday, April 30th. JPMorgan Chase & Co. began coverage on Xylem in a research report on Friday, May 30th. They set an "overweight" rating and a $148.00 target price on the stock. Raymond James Financial raised shares of Xylem to a "hold" rating in a research report on Thursday, May 15th. Robert W. Baird reduced their target price on Xylem from $149.00 to $146.00 and set an "outperform" rating for the company in a report on Wednesday, April 30th. Finally, Citigroup lowered their target price on shares of Xylem from $152.00 to $134.00 and set a "buy" rating on the stock in a research report on Monday, April 14th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $143.71.

Check Out Our Latest Analysis on Xylem

About Xylem

(Free Report)

Xylem Inc, together with its subsidiaries, engages in the design, manufacture, and servicing of engineered products and solutions worldwide. It operates through four segments: Water Infrastructure, Applied Water, Measurement & Control Solutions, and Integrated Solutions and Services. The Water Infrastructure segment offers products, including water, storm water, and wastewater pumps; controls and systems; filtration, disinfection, and biological treatment equipment; and mobile dewatering equipment and rental services under the ADI, Flygt, Godwin, Sanitaire, Magneto, Neptune Benson, Ionpure, Leopold, Wedeco, and Xylem Vue brands.

Read More

Institutional Ownership by Quarter for Xylem (NYSE:XYL)

Should You Invest $1,000 in Xylem Right Now?

Before you consider Xylem, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xylem wasn't on the list.

While Xylem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore
AI Stocks Are Printing Money — These 3 Are Just Getting Started

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines